Cancer Targeted Therapy Market & Clinical Insight 2015

がん分子標的治療の世界市場及びインサイト

◆タイトル:Cancer Targeted Therapy Market & Clinical Insight 2015
◆商品コード:KUICK504095
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年4月
◆ページ数:2900
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD6,600 ⇒換算¥712,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、がん分子標的治療の世界市場について調査・分析し、がん分子標的治療のニーズ、がん分子標的治療の仕組み、ナノメディシンの世界市場概要、市場の動態、市場展望、がん分子標的モノクローナル抗体のパイプライン動向、がんワクチンのパイプライン動向、原癌遺伝子タンパク質のパイプライン動向、チロシンキナーゼのパイプライン動向、上市品分析、主要企業分析等の情報をお届けいたします。

Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles.

Small molecules cancer targeted therapeutics could be further divided into several categories depending upon cancer indications and target type. For instance, Gleevec by Novartis is tyrosine kinase inhibitor which is used in chronic myelogenous leukemia. Zelboraf by Roche is used for melanoma treatment which is a serine threonine kinase inhibitor. Multiple target inhibitors could also be observed in this segment which could be assigned to different cancer segments. Such capabilities allow them to erode profit margins of other drugs belonging to same and other cancer indications. It should also be noted that a single small molecule could fall in several segments due to which it could be used in lieu of similar drug. For instance, Lapatinib by GalaxoSmithKline acts on Her2/neu receptors and EGFR pathways related to breast cancer and lung cancer. Multiple target inhibitors contain both small and large molecule cancer targeted therapeutics. Various big pharmaceutical companies like Boehringer Ingelheim, Johnson & Johnson, Teva, Eli Lily and others are actively engaged in development of these molecules. Customizability of a molecule is among important factors that helps in increasing their market shares.

Large molecules like monoclonal antibodies are highly customizable due to which they could be formulated according to necessities of drug development program. Due to high versatility, they have been developed to target various molecules specific to particular cancer types. New target discovery could be considered as one of the most important factors affecting market growth of large molecule cancer targeted therapeutics. As compared to small molecule cancer targeted molecules, they have better pharmacological profiles and target binding efficacy due to which they would be able to occupy major market shares across the globe in coming years. They are still at emerging stages of industry life cycles due to which they offer significant marketing potential.

Clinical pipeline of innovative targeted therapeutics is increasing continuously due to which pharmaceutical companies would be able to generate more revenues. For instance, early diagnosis is a pre requisite of cancer patients undergoing cancer treatment. Paper carrying synthetic target molecule on surface is proposed to be used for identifying different cancers by soaking it in potential patient’s urine. Such tests are expected to be marketed in underdeveloped countries where early cancer diagnosis tests are costly. Other uses of nanotechnology is being discovered by investigators so that they could directly target specific molecules without affecting neighboring cells. Further, new biomarkers are at various phases of clinical trials that would be able to introduce new cancer targeted therapeutics in global market in coming years.

Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report:

• Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI
• Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors
• Cancer Vaccines Pipeline: 289 Cancer Vaccines
• Cancer Targeted Monoclonal Antibodies: 605 mAb
• Oncogene Inhibitors Pipeline: 185 oncogene inhibitors

“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:

• Introduction & Categorization of Cancer Targeted Therapies
• Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
• Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
• Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
• Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
• Global Cancer Targeted Therapeutics Market Dynamics
• Future Prospects of Cancer Targeted Therapies

【レポートの目次】

1. Introduction to Cancer Targeted Therapeutics

2. Need for Cancer Targeted Therapeutics

3. Categorization of Cancer Targeted Therapies

4. Consideration of Cancer Vaccines as Targeted Therapeutics

5. Mechanism of Cancer Vaccines
5.1 Idiotype Cancer Vaccine Mechanism
5.2 Cellular Cancer Vaccines Mechanism
5.3 Ganglioside Antigens based Cancer Vaccines Mechanism
5.4 Peptide Cancer Vaccine Mechanism
5.5 Tumor Host Interaction Cancer Vaccine Mechanism

6. Mechanisms of Cancer Targeted Monoclonal Antibodies
6.1 Tumor Antigens as Targets of Antibodies
6.2 Development of Antibodies for Clinical Purposes
6.3 Complement Dependent Cytotoxicity (CDC)
6.4 Signal Transduction Changes

7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics

8. Mechanism of Oncogene Inhibitors

9. Global Cancer Targeted Therapy Market Overview
9.1 Current Market Scenario
9.2 Cancer Targeted Therapy Clinical Pipeline Insight

10. Global Cancer Targeted Therapeutics Market Dynamics
10.1 Favorable Market Parameters
10.2 Commercialization Challenges

11. Future Prospects of Cancer Targeted Therapeutics

12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase I
12.6 Phase I/II
12.7 Phase II
12.8 Phase II/III
12.9 Phase III
12.10 Preregistration
12.11 Registered

13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country

14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

16. Oncogene Inhibitors Pipeline by Company, Indication & Phase
16.1 Oncogene Protein Inhibitors Pipeline
16.2 Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline
16.3 Proto Oncogene Protein b raf Inhibitors Pipeline
16.4 Proto Oncogene Protein c-kit Inhibitors Pipeline
16.5 Proto-Oncogene Protein c-rel Inhibitors Pipeline
16.6 Proto Oncogene Protein c-akt Inhibitors Pipeline
16.7 Proto Oncogene Protein c met Inhibitors Pipeline
16.8 Proto Oncogene Protein c ret Inhibitors Pipeline
16.9 Proto-Oncogene Protein c mdm2 Inhibitors Pipeline
16.10 Proto-Oncogene Protein Inhibitors Pipeline
16.11 Proto-Oncogene-Protein-c-ets Inhibitors Pipeline
16.12 Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline
16.13 Proto Oncogene Proteins c pim 1 Inhibitors Pipeline
16.14 Proto Oncogene Protein c-myc Inhibitors Pipeline
16.15 Multiple Oncogene Inhibitors Pipeline

17. Marketed Oncogene Inhibitors by Company & Indication

18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase
18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered

19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors

20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication
20.1 Unknown
20.2 Research
20.3 Preclinical
20.4 Clinical
20.5 Phase-I
20.6 Phase-I/II
20.7 Phase-II
20.8 Phase-III

21. Marketed Cancer Targeted Angiogenesis Inhibitors

22. Competitive Landscape
22.1 Advaxis
22.2 Bind Therapeutics
22.3 Boehringer Ingelheim
22.4 Bristol Mayer Squibb
22.5 Celldex Therapeutics
22.6 Dendreon Corporation
22.7 Eli Lily
22.8 GalaxoSmithKline
22.9 Galena Biopharma
22.10 Genetech
22.11 ImmunoCellular Therapeutics
22.12 ImmunoGen
22.13 Inovio Pharmaceuticals
22.14 Johnson & Johnson
22.15 NeoStem Oncology
22.16 NewLink Genetics
22.17 Northwest Biotherapeutics
22.18 Merck
22.19 Novartis
22.20 Peregrine Pharmaceuticals
22.21 Pfizer
22.22 Roche
22.23 Sanofi
22.24 Seattle Genetics
22.25 Teva

Figure 1-1: Uses of Pharmacogenomics
Figure 1-2: Developmental Stages of Targeted Therapeutics
Figure 1-3: Cancer Target Identification Techniques
Figure 1-4: Genetic Anomalies Classification
Figure 1-5: Mechanism of Cancer Targeted Therapeutics
Figure 1-6:Improvements Required for Cancer Targeted Therapies
Figure 2-1: Objectives of Cancer Targeted Therapeutics
Figure 2-2: Benefits of Cancer Targeted Therapeutics
Figure 3-1: Categorization of Cancer Targeted Therapeutics on the Basis of Molecular Size
Figure 3-2: Features of Cancer Targeted Small Molecules Drugs
Figure 3-3: Features of Cancer Targeting Antibodies
Figure 3-4: Classification of Cancer Targeted Therapies on the Basis of their Mechanism
Figure 4-1: Classification of Cancer Vaccines
Figure 4 2: Distinction of Cancer Vaccines
Figure 5-1: Classification of Different Types of Cancer vaccines
Figure 7-1: Benefits of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-2: Classification of Tyrosine Kinase
Figure 7-3: Mechanism of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-4: Mechanism of VEGFR
Figure 8-1: Activation of Proto-Oncogenes to Oncogenes
Figure 8-2:Benefits of Oncogene Inhibitors
Figure 8-3: Mechanism of Crizotinib
Figure 8-4: Mechanism of Vemurafenib
Figure 8-5: Mechanism of Vorinostat
Figure 9-1: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2015
Figure 9-2: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2015
Figure 9-3: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2015
Figure 9-4: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2015
Figure 9-5: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 9-6: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 9-7: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-8: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-9: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 9-10: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 9-11: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 9-12: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 9-13: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 9-14: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 9-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 9-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 9-17: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 9-18: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 9-19: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-20: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-21: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 9-22: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-23: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 9-24: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 9-25: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 9-26: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 9-27: Angienesis Inhibitors Pipeline by Phase (%), 2015
Figure 9-28: Angienesis Inhibitors Pipeline by Phase (Number), 2015
Figure 22-1: Advaxis Clinical Pipeline
Figure 22-2: Celldex Therapeutics Clinical Pipeline
Figure 22-3: Galena Biopharma Clinical Pipeline
Figure 22-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 22-5: ImmunoGen Clinical Pipeline
Figure 22-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 22-7: NewLink Genetics Corporation Clinical Pipeline
Figure 22-8: Northwest Biotherapeutics Clinical Pipeline
Figure 22-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 22-10: Seattle Genetics Clinical Pipeline


Table 2-1: Difference between Chemotherapeutics & Targeted Therapeutics
Table 3-1: Suffix used for Targeted Therapeutics
Table 3-2: Naming of Small Molecule Targeted Therapeutics
Table 3-3: Nomenclature of Monoclonal Antibodies
Table 9-1: Breast Cancer Targeted Therapeutics
Table 9-2: Lung Cancer Targeted Therapeutics


【掲載企業】

Advaxis, Bind Therapeutics, Boehringer Ingelheim, Bristol Mayer Squibb, Celldex Therapeutics, Dendreon Corporation, Eli Lily, GalaxoSmithKline, Galena Biopharma, Genetech, ImmunoCellular Therapeutics, ImmunoGen, Inovio Pharmaceuticals, Johnson & Johnson, NeoStem Oncology, NewLink Genetics, Northwest Biotherapeutics, Merck, Novartis, Peregrine Pharmaceuticals, Pfizer, Roche, Sanofi, Seattle Genetics, Teva



【レポートのキーワード】

がん分子標的治療、がんワクチン、モノクローナル抗体、チロシンキナーゼ、原癌遺伝子タンパク質、癌治療、医薬品、パイプライン

★調査レポート[がん分子標的治療の世界市場及びインサイト] ( Cancer Targeted Therapy Market & Clinical Insight 2015 / KUICK504095) 販売に関する免責事項
[がん分子標的治療の世界市場及びインサイト] ( Cancer Targeted Therapy Market & Clinical Insight 2015 / KUICK504095) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆